(.pdf) dr.ssa Antonella Ferro - Progettoeventi
(.pdf) dr.ssa Antonella Ferro - Progettoeventi (.pdf) dr.ssa Antonella Ferro - Progettoeventi
MBC I linea II linea HO648 M77001 US Oncology BCIRG 007 CHAT Tandem Rhea Studi clinici con Trastuzumab GBG-26 Studi Fase II Neo NOAH MDACC GeparQuattro Studi Fase II EBC HERA Adj NSABP-B31 NCCTG N9831 BCIRG 006 FinHER PACS-04
Trastuzumab binds to ErbB2 on tumour cells Trastuzumab binds to the extracellular domain of ErbB2 to induce anti-tumour effect Immune cells bind to trastuzumab and release substances that promote tumour cell death • Effect of trastuzumab on cell signalling not well understood • Activity has been attributed to antibody-dependent cellular cytotoxicity (ADCC) 1–4 1. Nahta & Esteva. Breast Cancer Res 2006;8:215; 2. Clynes et al. Nat Med 2000;6:443–6; 3. Gennari et al. Clin Cancer Res 2004;10:5650–5; 4. Arnould et al. Br J Cancer 2006;94:259–67
- Page 1 and 2: Utilizzo dei farmaci nei diversi co
- Page 3 and 4: HER2 positive breast cancer “Targ
- Page 5: Trastuzumab (Herceptin) • Il Tras
- Page 9 and 10: Antibody-Dependent Cellular Cytotox
- Page 11 and 12: Potenziale meccanismo di trastuzuma
- Page 13: Malattia adiuvante
- Page 17 and 18: DFS: Sequential (Arm B: AC → T
- Page 19 and 20: Malattia Neo- adiuvante
- Page 21 and 22: Studio NOAH: Event Free Survival ne
- Page 23 and 24: Trastuzumab has transformed the pro
- Page 25 and 26: Definition of resistance In most tu
- Page 27 and 28: Truncated HER2 (p95 HER2 ): clinica
- Page 29 and 30: Trastuzumab Capecitabine von Minckw
- Page 31 and 32: GBG 26/BIG 03-05: main results Cape
- Page 33 and 34: Phase III, randomised, controlled s
- Page 35 and 36: Lapatinib • Binds to intracellula
- Page 37 and 38: Lapatinib may sensitise HER2 positi
- Page 39 and 40: Pertuzumab • Pertuzumab, inibitor
- Page 41 and 42: HER2 dimerization is key to signali
- Page 43 and 44: Trastuzumab binds to subdomain IV o
- Page 45 and 46: Trastuzumab and pertuzumab may have
- Page 47 and 48: Receptor-T-DM1 complex is internali
Trastuzumab<br />
binds to ErbB2<br />
on tumour cells<br />
Trastuzumab binds to the extracellular domain of<br />
ErbB2 to induce anti-tumour effect<br />
Immune cells bind to trastuzumab and release<br />
substances that promote tumour cell death<br />
• Effect of trastuzumab on cell signalling not well understood<br />
• Activity has been attributed to antibody-dependent cellular<br />
cytotoxicity (ADCC) 1–4<br />
1. Nahta & Esteva. Breast Cancer Res 2006;8:215; 2. Clynes et al. Nat Med 2000;6:443–6; 3. Gennari et al. Clin Cancer Res<br />
2004;10:5650–5; 4. Arnould et al. Br J Cancer 2006;94:259–67
Change language